van Kopen et al reported a long term therapeutic rescue function in chronic kidney disease. An MSC produced conditioned medium, administered intravenously, decreased progression of CKD and reduced hypertension and glomerular injury.
Monthly Archives: June 2012
In this study by Chae et al. published in the Biochemical Journal, 26 differentially expressed proteins were identified as being critical to the etiology of HD. In particular, superoxide dismutase 1 (SOD1) and peroxiredoxins are significantly affected, implying the significance of oxidative stress in HD.
Once again, the value of iPSC in disease modelling is demonstrated.
The lack of any progress in Stem Cell Legislation in Ireland is extremely frustrating. Apart from the obvious limitations to scientific advancement and regenerative medicine, the potential loss of inward investment by large multinationals is equally concerning. Companies such as Merck-Millipore and Pfizer (both existing players in the Irish Pharmaceutical Industry) are all investing heavily in Stem Cells for their potential in drug discovery. The worry is that these multinationals will simply bypass Ireland on future projects.
A major debate is imminent with the existing Irish Stem Cell Foundation now being joined by the Adult Stem Cell foundation of Ireland. This is a serious debate with many stakeholders holding opposing views. The Irish government needs to prioritise progress in this regard and facilitate both organisations if they are indeed committed to future investment in the Biotech and Pharmaceutical industries.
Seeing how long it has taken to even raise awareness among the political class, who knows how long the ESC v hIPSC debate will take….
Can this country at least start the ball rolling on this subject?!! I see trouble on the horizon
Challenging existing theories on vascular remodelling and diseases, a paper by Tang et al describes how multipotent vascular stem cells contribute to vascular remodelling by differentiating into smooth muscle cells and chondrogenic cells.
Image: Song Li
Recent work by Gepstein et al published in the European Heart Journal demonstrates the valuable potential of hiPSCs in cardiovascular regeneration.
The ability to source patient specific cells will avoid the use of allogenic grafts with their inherent rejection issues. In this case, dermal fibroblasts were reprogrammed using viral delivery of pluripotency factors and subsequently coaxed into differentiating to cardiomyocyte cells.
While this is an emerging field, this early work holds much promise and is great news for proponents of hiPSCs
Article source here: